GSK settles two California lawsuits related to heartburn drug Zantac
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...
Japan to review GSK's Blenrep drug application
Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.
pharmaphorum6d
ESMO: GSK, iTeos bring some optimism back to TIGIT
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...
BioSpace5d
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
GSK: Japan Accepts For Review NDA For Blenrep Combinations In Relapsed/refractory Multiple Myeloma
Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...
AOL4d
GSK settles two California lawsuits related to heartburn drug Zantac
(Reuters) - British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any ...
GSK Settles 2 Cases In California Against Zantac
Drug maker GSK plc (GSK, GSK.L) confirmed Wednesday that it has reached two confidential settlements in cases filed in California ...
The Globe and Mail3d
Head and Neck Cancer Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024
DelveInsight’s, “Head and Neck Cancer Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and ...